QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 personalis-announces-phase-3-laura-trial-data-with-astrazeneca-showing-next-personal-mrd-test-effectively-assesses-post-crt-response-in-egfrm-stage-iii-nsclc

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...

 hc-wainwright--co-reiterates-buy-on-personalis-maintains-85-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8.5 pri...

 personalis-announces-new-data-from-astrazeneca-phase-3-clinical-trial-in-lung-cancer-showing-personalis-mrd-test-next-personal-is-strong-predictor-of-outcomes-in-patients-with-stage-ii-iiib-egfr-mutated-nsclc-receiving-neoadjuvant-therapy

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...

 hc-wainwright--co-maintains-buy-on-personalis-lowers-price-target-to-85

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price ta...

 personalis-lowers-fy2025-sales-guidance-from-80000m-90000m-to-70000m-80000m-vs-83326m-est

Personalis (NASDAQ:PSNL) lowers FY2025 sales outlook from $80.000 million-$90.000 million to $70.000 million-$80.000 million vs...

 personalis-sees-q3-sales-12000m-14000m-vs-18874m-est

Personalis (NASDAQ:PSNL) sees Q3 sales of $12.000 million-$14.000 million vs $18.874 million analyst estimate.

 personalis-q2-eps-023-beats-024-estimate-sales-17203m-miss-20114m-estimate

Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by...

 cramer-says-tesla-dominates-while-ouster-is-too-speculative

Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternat...

Core News & Articles

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer typesPersonalis, Inc. (NASDA...

 personalis-presents-new-results-from-calla-phase-3-study-showing-for-first-time-ultrasensitive-next-personal-ctdna-blood-test-detected-cervical-cancer-progression-up-to-16-months-ahead-of-imaging

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results...

 personalis-presents-new-clinical-results-from-predict-dna-and-scandare-studies-highlighting-capabilities-of-ultrasensitive-next-personal-ctdna-blood-test-for-monitoring-and-predicting-nat-response-in-tnbc

Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinica...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION